Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (294)	5/28/2003 12:48:24 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

Vion Initiates Phase 2 Trial Of Triapine, Gemcitabine DOW JONES NEWSWIRES NEW HAVEN -- Vion Pharmaceuticals Inc. (VION) began a new Phase 2 trial of Triapine in combination with gemcitabine in patients with metastatic or advanced pancreatic cancer. Enrollment began at the Sara Cannon Cancer Center in Nashville under the direction of Dr. Howard Burris, the biopharmaceutical company said in a press release Wednesday. Data from the Phase 1 trial of Triapine and gemcitabine will be presented in a poster presentation at the American Society of Clinical Oncology Annual Meeting in June. Last week, Vion said it began a similar Phase 2 trial of Triapine and gemcitabine in patients with non-small-cell lung cancer. Triapine is designed to be a potent inhibitor of ribonucleotide reductase, an enzyme important for DNA synthesis. Gemcitabine is sold under the brand name Gemzar by Eli Lilly & Co. (LLY). Shares of Vion were trading recently at $1.40, up 23 cents, or 19.7%, on volume of 959,418 shares. Average daily volume is 266,372 shares. Company Web site: vionpharm.com